Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
A phase 3 trial of Datopotamab deruxtecan, Rilvegostomig, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT06357533 by AstraZeneca, with 675 participants planned, started 2024-04-11 and due to reach its primary completion in 2029-12-28. Interventions recorded: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Non-small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C
Shares Rilvegostomig, Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer.